Zeynep Aydi, MD
Surgical Oncology · Phoenix, AZNPI 1487881710
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (50.3%), travel and lodging and education — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Axogen at 47.1% of the total.
Across 80 payments — averaging $54.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axogen$2K
- Bioptics, Inc.$509
- Focal Therapeutics, Inc.$383
- Novartis$126
- Foundation Medicine, Inc.$125
- AstraZeneca$119
- plus $1K from 26 others
What the payments were for
- Travel & lodging$2,15449%
- Food & beverage$2,20750%
- Education$301%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axogen | 6 | $2,070 |
| Bioptics, Inc. | 2 | $509 |
| Focal Therapeutics, Inc. | 1 | $383 |
| Novartis | 9 | $126 |
| Foundation Medicine, Inc. | 2 | $125 |
| AstraZeneca(2 entities) | 7 | $119 |
| Bristol Myers Squibb | 5 | $115 |
| Johnson & Johnson | 6 | $98 |
| Hologic Inc | 1 | $91 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $86 |
| Sanofi | 5 | $78 |
| Bayer | 4 | $64 |
| Seagen Inc. | 2 | $62 |
| AbbVie | 3 | $59 |
| Rigel Pharmaceuticals, Inc. | 2 | $45 |
| Amgen | 2 | $40 |
| Daiichi Sankyo Inc. | 3 | $39 |
| Merck | 2 | $37 |
| AMAG Pharmaceuticals, Inc. | 2 | $30 |
| Ipsen Biopharmaceuticals, Inc | 1 | $22 |
| Boston Scientific | 1 | $22 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Lexicon Pharmaceuticals, Inc. | 1 | $20 |
| KCI USA, Inc. | 1 | $19 |
| Sun Pharmaceutical Industries Inc. | 1 | $17 |
| Karyopharm Therapeutics Inc. | 1 | $15 |
| Advanced Oxygen Therapy Inc. | 1 | $15 |
| Lilly USA, LLC | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Pfizer | 1 | $13 |
| Advanced Accelerator Applications | 1 | $12 |
| Boehringer Ingelheim | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AXOGUARD$4,073
- AXOGUARD HA+ NERVE PROTECTOR$2,037
- AxoGuard Nerve Cap$2,037
- Localizer$509
- BioZorb$348
- Trunode$348
- TRIDENT$348
- FOUNDATIONONE$109
- FOUNDATIONONE HEME$109
- FOUNDATIONONE CDX$109
- FOUNDATIONFOCUS$109
- FOUNDATIONONE LIQUID$109
How this compares
$4,391 in reported general payments places this provider in the 75th percentile of 29 surgical oncology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other surgical oncology in Phoenix
- David JacofskyPhoenix$11.3M
- Dipak RamkumarPhoenix$148K
- Zhi Ven FongPhoenix$7K
- William CancePhoenix$2K
- Jason WisemanPhoenix$96
- Mark GimbelGilbert$14K
- Taylor RiallTucson$6K
- Rohit SahaiChandler$5K
- Sivakami MoorthyGlendale$5K
- Mohammad KhreissTucson$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.